Warning for lopinavir/ritonavir oral solution
The US Food and Drug Administration has notified health care practitioners that severe, possibly fatal, health problems have been reported in babies who have received lopinavir/ritonavir oral solution.
The US Food and Drug Administration (FDA) has notified health care practitioners that severe, possibly fatal, health problems have been reported in babies who have received lopinavir/ritonavir oral solution.
Lopinavir/Ritonavir oral solution is an antiviral medication containing alcohol and propylene glycol that is used in combination with other antiretroviral drugs to treat human immunodeficiency virus (HIV-1) infection .
Preterm neonates have a decreased ability to eliminate propylene glycol, which could lead to adverse events including serious heart, kidney, and respiratory problems.
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Identifying benign lesions in female patients by new algorithm
October 6th 2023In this Q+A interview originally conducted by our sister publication, Contemporary OB/GYN, Peter Minneci, MD, MHSc, discusses a study evaluating a new algorithm capable of accurately identifying benign lesions in female patients.
